Company: TEM
Filing Date: 2025-03-07
Form Type: 424B3
Source: 0001193125-25-049935
Chunk: 4

Company: Tempus AI, Inc.
Filing Date: 2025-03-07
Form: 424B3
Chunk 4
---
 information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. iv

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere in this prospectus and in the documents we incorporate herein by reference, and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, along with our consolidated financial statements and the related notes thereto and the information set forth in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in or incorporated herein by reference. Unless the context otherwise requires, we use the terms “Tempus,” “Company,” “we,” “us” and “our” in this prospectus to refer to Tempus AI, Inc. and its consolidated subsidiaries.

Overview

Tempus is a healthcare technology company that straddles two converging worlds. We strive to combine deep healthcare expertise,
providing next-generation diagnostics across multiple disease areas, with leading technology capabilities, harnessing the power of data and analytics to help personalize medicine. We endeavor to unlock the true power of precision medicine by
creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. Unlike
traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data, with the goal of making our tests more intelligent and our results more insightful. Unlike other technology companies, we are
deeply rooted in clinical care delivery as one of the largest sequencers of cancer patients, and patients with other diseases, in the United States. Straddling both worlds is advantageous as we believe Intelligent Diagnostics represent the future of
precision medicine, informing more personalized and data-driven therapy selection and development. We believe the adoption of Intelligent Diagnostics could empower physicians to deliver better care and researchers to develop more precise therapies,
with the potential to save millions of lives.

In order to bring AI to healthcare at scale, we established new data pipes,
going to and from providers, to allow for the free exchange of data between physicians, who interpret data, and diagnostic